This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages before signing in

NICE guidance - diabetic neuropathy

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

  • NICE suggest that (1,3):
    • for treatment of all neuropathic pain (except trigeminal neuralgia)
      • offer a choice of amitriptyline, duloxetine as initial treatment for neuropathic pain

      • if the initial treatment is not effective or is not tolerated, offer one of the remaining 3 drugs, and consider switching again if the second and third drugs tried are also not effective or not tolerated

      • consider tramadol only if acute rescue therapy is needed

      • consider capsaicin cream for people with localised neuropathic pain who wish to avoid, or who cannot tolerate, oral treatments
      • when withdrawing or switching treatment, taper the withdrawal regimen to take account of dosage and any discontinuation symptoms

For NICE guidance regarding management of chronic pain (pain that lasts for more than 3 months) then see linked item.

In this guidance (3) NICE state that antiepileptic drugs including gabapentinoids should not be initiated to manage chronic primary pain in people aged 16 years and over.

Reference:

Related pages

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.